Your browser doesn't support javascript.
loading
Impact of pembrolizumab versus chemotherapy on health-related quality of life in patients with metastatic triple-negative breast cancer: results from the phase 3 randomised KEYNOTE-119 study.
Schmid, Peter; Lipatov, Oleg; Im, Seock-Ah; Goncalves, Anthony; Muñoz-Couselo, Eva; Lee, Keun Seok; Tamura, Kenji; Testa, Laura; Witzel, Isabell; Ohtani, Shoichiro; Turner, Nicholas; Zambelli, Stefania; Harbeck, Nadia; Andre, Fabrice; Dent, Rebecca; Mejia, Jaime A; Zhou, Xuan; Haiderali, Amin; Nguyen, Allison Martin; Cortes, Javier; Winer, Eric P.
Afiliación
  • Schmid P; Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University London, London, UK. Electronic address: p.schmid@qmul.ac.uk.
  • Lipatov O; Medical Oncology, Republican Clinical Oncology Dispensary, Ufa, Republic of Bashkortostan, Russia.
  • Im SA; Internal Medicine, Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
  • Goncalves A; Department of Medical Oncology, Institut Paoli-Calmettes, Centre de Recherche en Cancérologie de Marseille, Aix-Marseille University, Centre National de la Recherche Scientifique, French National Institute of Health and Medical Research, Marseille, France.
  • Muñoz-Couselo E; International Breast Cancer Center, Quiron Group, Madrid and Barcelona, Spain and Vall d'Hebron Institute of Oncology, Barcelona, Spain.
  • Lee KS; Center for Breast Cancer, National Cancer Center, Goyang, Republic of Korea.
  • Tamura K; Department of Breast and Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Testa L; Breast Medical Oncology, Instituto do Câncer do Estado de São Paulo, Faculdade de Medicina da Universidade do Estado do São Paulo, São Paulo, Brazil.
  • Witzel I; Department of Gynecology, University Medical Center Zurich, University of Zurich, Zurich, Switzerland.
  • Ohtani S; Surgical Oncology, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan.
  • Turner N; Breast Unit, The Royal Marsden and Institute of Cancer Research, London, UK.
  • Zambelli S; Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico Ospedale San Raffaele, Milan, Italy.
  • Harbeck N; Breast Center, Department of Obstetrics and Gynecology and Comprehensive Cancer Center (CCC) Munich, Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany.
  • Andre F; Gustave Roussy Cancer Center, Paris Saclay University, Villejuif, France.
  • Dent R; Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
  • Mejia JA; Late Stage Drug Development, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Zhou X; Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Haiderali A; Center for Observational and Real-World Evidence, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Nguyen AM; Biostatistics and Research Decision Sciences - Epidemiology, Patient-Centered Endpoints & Strategy, Merck & Co., Inc., Rahway, New Jersey, USA.
  • Cortes J; Department of Medicine, International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Barcelona, Spain, & Faculty of Biomedical and Health Sciences, Universidad Europea de Madrid, Madrid, Spain.
  • Winer EP; Division of Breast Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Eur J Cancer ; 195: 113393, 2023 12.
Article en En | MEDLINE | ID: mdl-37976633
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Neoplasias de la Mama Triple Negativas Límite: Humans Idioma: En Revista: Eur J Cancer Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Calidad de Vida / Neoplasias de la Mama Triple Negativas Límite: Humans Idioma: En Revista: Eur J Cancer Año: 2023 Tipo del documento: Article